fasudil has been researched along with Chronic Disease in 15 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction." | 9.07 | Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. ( Hatazawa, J; Hirata, Y; Kanno, I; Kondoh, Y; Nagata, K; Satoh, Y; Shishido, F; Watahiki, Y; Yokoyama, E; Yuya, H, 1993) |
| "To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction." | 5.07 | Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. ( Hatazawa, J; Hirata, Y; Kanno, I; Kondoh, Y; Nagata, K; Satoh, Y; Shishido, F; Watahiki, Y; Yokoyama, E; Yuya, H, 1993) |
| "To investigate the effect of fasudil, a Rho-kinase inhibitor, on chronic ischemia-related bladder dysfunction." | 3.88 | Protective Effect of a Rho-kinase Inhibitor on Bladder Dysfunction in a Rat Model of Chronic Bladder Ischemia. ( Aikawa, K; Akaihata, H; Haga, N; Hata, J; Ishibashi, K; Koguchi, T; Kojima, Y; Kushida, N; Matsuoka, K; Nomiya, M, 2018) |
| "Fasudil treatment notably ameliorated ADR-induced cardiac damage, restored heart function, suppressed cell apoptosis and senescence, ameliorated redox imbalance, and DNA damage." | 1.56 | Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury. ( Miao, D; Xiang, C; Yan, Y; Yang, Z; Zhang, D, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, Y | 1 |
| Xiang, C | 1 |
| Yang, Z | 1 |
| Miao, D | 1 |
| Zhang, D | 2 |
| Detter, MR | 1 |
| Shenkar, R | 1 |
| Benavides, CR | 1 |
| Neilson, CA | 1 |
| Moore, T | 1 |
| Lightle, R | 1 |
| Hobson, N | 1 |
| Shen, L | 1 |
| Cao, Y | 1 |
| Girard, R | 1 |
| Griffin, E | 1 |
| Gallione, CJ | 1 |
| Awad, IA | 1 |
| Marchuk, DA | 1 |
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Akaihata, H | 1 |
| Nomiya, M | 1 |
| Matsuoka, K | 1 |
| Koguchi, T | 1 |
| Hata, J | 1 |
| Haga, N | 1 |
| Kushida, N | 1 |
| Ishibashi, K | 1 |
| Aikawa, K | 1 |
| Kojima, Y | 1 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Ziino, AJ | 1 |
| Ivanovska, J | 2 |
| Belcastro, R | 1 |
| Kantores, C | 2 |
| Xu, EZ | 2 |
| Lau, M | 1 |
| McNamara, PJ | 2 |
| Tanswell, AK | 1 |
| Jankov, RP | 2 |
| Yoshimi, E | 1 |
| Kumakura, F | 1 |
| Hatori, C | 1 |
| Hamachi, E | 1 |
| Iwashita, A | 1 |
| Ishii, N | 1 |
| Terasawa, T | 1 |
| Shimizu, Y | 1 |
| Takeshita, N | 1 |
| Engelberts, D | 1 |
| Kavanagh, BP | 1 |
| Blood, AB | 1 |
| Terry, MH | 1 |
| Merritt, TA | 1 |
| Papamatheakis, DG | 1 |
| Blood, Q | 1 |
| Ross, JM | 1 |
| Power, GG | 1 |
| Longo, LD | 1 |
| Wilson, SM | 1 |
| Haack, KK | 1 |
| Gao, L | 1 |
| Schiller, AM | 1 |
| Curry, PL | 1 |
| Pellegrino, PR | 1 |
| Zucker, IH | 1 |
| Satoh, Si | 1 |
| Ikegaki, I | 2 |
| Toshima, Y | 1 |
| Watanabe, A | 1 |
| Asano, T | 2 |
| Shimokawa, H | 2 |
| Nagaoka, T | 1 |
| Fagan, KA | 1 |
| Gebb, SA | 1 |
| Morris, KG | 1 |
| Suzuki, T | 1 |
| McMurtry, IF | 1 |
| Oka, M | 1 |
| Guilluy, C | 1 |
| Sauzeau, V | 1 |
| Rolli-Derkinderen, M | 1 |
| Guérin, P | 1 |
| Sagan, C | 1 |
| Pacaud, P | 1 |
| Loirand, G | 1 |
| Nagata, K | 1 |
| Kondoh, Y | 1 |
| Satoh, Y | 1 |
| Watahiki, Y | 1 |
| Yokoyama, E | 1 |
| Yuya, H | 1 |
| Hirata, Y | 1 |
| Shishido, F | 1 |
| Hatazawa, J | 1 |
| Kanno, I | 1 |
| Shibuya, M | 1 |
| Suzuki, Y | 1 |
| Takayasu, M | 1 |
| Harada, T | 1 |
| Satoh, S | 1 |
| Hidaka, H | 1 |
1 review available for fasudil and Chronic Disease
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
1 trial available for fasudil and Chronic Disease
| Article | Year |
|---|---|
Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blood Pressure; Calcium Channel Blockers; Cereb | 1993 |
13 other studies available for fasudil and Chronic Disease
| Article | Year |
|---|---|
Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Apoptosis; Biomarkers; Cardiot | 2020 |
Novel Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Apoptosis Regulatory Proteins | 2020 |
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Protective Effect of a Rho-kinase Inhibitor on Bladder Dysfunction in a Rat Model of Chronic Bladder Ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chronic Disease; Disease Models, Animal; Isc | 2018 |
Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Airway Remodeling; Amides; Animals; Animals, Newborn; | 2010 |
Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analgesics; Analgesics, Opioid; Animals; Anti-Inflamm | 2010 |
Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Age Factors; Aging; Amides; Animals; Apoptosis; Cell | 2010 |
Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Altitude; Animals; Animals, Newborn; Arterial Pressur | 2013 |
Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Brain Stem; Chronic Disease; Con | 2013 |
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathies; Chronic Disease; Disease M | 2002 |
Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Administration, Oral; Ami | 2005 |
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Carrier Proteins; Chronic Disease; C | 2005 |
The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Calcium Channel Blockers; Cerebral | 1988 |